Merrimack Pharmaceuticals, Inc
Merrimack Pharmaceuticals, Inc logo
MACK

Merrimack Pharmaceuticals, Inc (MACK)

$11.880.25%

Market is closed
– opens on 8 PM, 05 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$11.85
Day's Range
$12.15
$3.0
52-Week Range
$13.66
1 month return184.21%
3 month return186.27%
1 year return189.76%
5 year return20.14%

Company Information

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $450.0 million in contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017. These milestone payments would be payable by Ipsen upon approval by the U.S. Food and Drug Administration ('FDA') of ONIVYDE® for certain additional clinical indications. ONIVYDE® is already approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. This existing approval is unrelated to any future potential milestone payments. Merrimack's agreement with Ipsen does not require Ipsen to provide Merrimack with any information on the progress of ONIVYDE® clinical trials that is not publicly available. Merrimack is also entitled to receive up to $54.5 million in contingent milestone payments related to its sale of anti-HER3 programs to Elevation Oncology (formerly 14ner Oncology, Inc.) in July 2019. The Company is seeking potential acquirers for its remaining preclinical assets.
OrganizationMerrimack Pharmaceuticals, Inc
Employees0
CEOMr. Gary L. Crocker M.B.A., MBA
IndustryHealth Technology

Analyst Recommendation

based on 8 analysts ratings

Sell
0%
Buy
50%
Hold
50%
Sell

Based on 8 Wall street analysts offering stock ratings for Merrimack Pharmaceuticals, Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Downside of 66.33%

Current

$11.88

Target

$4.0

Recommendation Trend

Based on 8 analyst

Current1M Ago3M Ago
Buy
0
0
0
Hold
4
4
4
Sell
4
4
4
Consensus
SELL
SELL
SELL

Highlights

Market Capitalization
158.9M
Book Value
$0.98
Dividend Share
0.0
Dividend Yield
57.699999999999996%
Earnings Per Share (EPS)
-0.14
PEG Ratio
0.07
Wall Street Target Price
4.0

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
12.23
Enterprise Value
148.2M
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
-72.66

Technicals

Beta
1.29
50 Day MA
6.26
200 Day MA
5.64

Institutional Holdings

Newtyn Management LLC

13.11%

22NW, LP

9.18%

Western Standard LLC

8.74%

Vanguard Group Inc

4.53%

Nantahala Capital Management, LLC

3.67%

Dimensional Fund Advisors, Inc.

3.52%

Discover more

Frequently Asked Questions

What is Merrimack Pharmaceuticals, Inc share price today?

Can Indians buy Merrimack Pharmaceuticals, Inc shares?

How can I buy Merrimack Pharmaceuticals, Inc shares from India?

Can Fractional shares of Merrimack Pharmaceuticals, Inc be purchased?

What are the documents required to start investing in Merrimack Pharmaceuticals, Inc stocks?

What are today’s High and Low prices of Merrimack Pharmaceuticals, Inc?

What are today’s traded volumes of Merrimack Pharmaceuticals, Inc?

What is today’s market capitalisation of Merrimack Pharmaceuticals, Inc?

What is the 52 Week High and Low Range of Merrimack Pharmaceuticals, Inc?

How much percentage Merrimack Pharmaceuticals, Inc is down from its 52 Week High?

How much percentage Merrimack Pharmaceuticals, Inc is up from its 52 Week low?

What are the historical returns of Merrimack Pharmaceuticals, Inc?

Who is the Chief Executive Officer (CEO) of Merrimack Pharmaceuticals, Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*